Policy & Regulations

This channel includes news coverage of healthcare policy and regulations set by Congress, the states, Centers for Disease Control and Prevention (CDC), the Department of Health and Human Services (HHS), U.S. Food and Drug Administration (FDA), and medical associations and societies. 

Thumbnail

CVS in ‘home stretch’ of antitrust process to acquire Aetna for $69B

CVS Health is in the “home stretch” of the regulatory process with the Justice Department and state regulators for its $69 billion merger with Aetna, according to CEO Larry Merlo.

Thumbnail

Andy Slavitt’s Town Hall Ventures raises $115M

Town Hall Ventures, the investment firm started by former CMS administrator Andy Slavitt, has raised $115 million.

Thumbnail

High cost of healthcare is an economic killer

With a large aging population and rising costs, healthcare spending is likely to have negative implications across the economy, according to a recent report from Moody’s.

Thumbnail

Healthcare spending rose 44% over last decade

Healthcare spending has risen rapidly over the last decade, jumping 44 percent per person across all major healthcare categories, according to a new study by the Health Care Cost Institute.

Thumbnail

WSJ: Secret hospital contracts prevent healthcare savings

Healthcare costs continue to balloon in the United States, and secret contracts between hospital systems and insurers may be playing a big role in keeping those costs up.

Thumbnail

Senate approves sweeping opioid bill

The Senate approved a major bill to tackle the opioid crisis with a nearly unanimous vote.

Thumbnail

Coca-Cola considers putting cannabis in a health drink

The Coca-Cola Company admitted it is taking a hard look at the use of cannabis in drinks after reports emerged that the company was in talks to develop a health drink infused with cannabidiol, a compound from the cannabis plant.

New CVS Health policy will exclude drugs above cost-effectiveness threshold

CVS Health will allow self-funded insurers to exclude some drugs from coverage if the cost is too high. The policy has been met with criticism from the pharmaceutical industry, which argues CVS is dividing treatment at arbitrary values.

Around the web

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

Trimed Popup
Trimed Popup